

Combo Drug Approved for Resistant Depression

BY DIANA MAHONEY

The Food and Drug Administration's recent approval of Eli Lilly's olanzapine/fluoxetine combination drug Symbyax for recalcitrant depression has been hailed as an important advance in the management of patients with major depressive disorder, but some experts still advise proceeding with caution.

Already approved for the treatment of bipolar depression, Symbyax is the first agent to be approved for acute therapy of treatment-resistant depression.

Approval of the combination antipsychotic/antidepressant was based on data from five trials demonstrating significant reductions in mean total Montgomery-Åsberg Depression Rating Scale (MADRS)



The data about weight gain with the combination therapy 'merit an important discussion.'

DR. PHILIP

scores relative to either fluoxetine alone or olanzapine alone among patients who met DSM-IV criteria for major depressive disorder (MDD) and who previously did not respond to two antidepressants of adequate dose and duration.

The studies evaluated fixed-combination doses ranging from 6 mg to 18 mg for olanzapine and 25 mg to 50 mg for fluoxetine, according to a press release from Eli Lilly & Co.

In an integrated analysis provided to the FDA by Eli Lilly, the reduction from baseline in mean MADRS scores for the combination drug vs. fluoxetine alone and olanzapine alone was -12.2 vs. -8.5 and -7.7, respectively. The remission rates for the combination, fluoxetine only, and olanzapine only were 25.5%, 17.3%, and 14.0%, respectively.

Pooled data from safety studies showed that, among the adverse events reported in at least 5% of the patients taking the combination drug, weight gain, increased appetite, dry mouth, somnolence, and fatigue were reported at twice the rate of patients in the placebo group.

Considering the large number of patients with treatment-resistant MDD—up to 35% of patients with depression, according to the data provided by Eli Lilly—the approval of the combination therapy is an important development, said Dr. Noah S. Philip of Brown University, Providence, R.I., who has studied the off-label use of atypical antipsychotic drugs in the treatment of depression.

"As the [Sequenced Treatment Alternatives to Relieve Depression] trial demonstrated, approximately one-half of patients respond and one-third remit during their first antidepressant trial, so more options are clearly needed, and use of the atypical antipsychotics as augmenting agents for depression is an increasing pat-

tern to fill this important need."

However, he noted, "there are still no trials comparing these newer, and much more expensive, augmentation strategies to other ... strategies such as lithium, T3, or bupropion augmentation."

There have also been concerns that definition of treatment-resistant depression in the olanzapine/fluoxetine combination studies might be too lax. "Operationally, the definition of treatment-re-

sistant depression is the failure of at least two previous trials in the current depressive episode [as in the data presented by Lilly to the FDA]," Dr. Philip said. "Other definitions include failure from at least two separate classes of antidepressants within a current major depressive episode, verified by scales such as the Antidepressant Treatment History Form, as well as failed trials of psychotherapy."

In addition, Dr. Philip said, the data

about weight gain with the combination therapy "merit an important discussion. Lilly's data showed that 56% of patients who received olanzapine/fluoxetine combination in longer term treatment (up to 76 weeks) had a more than 7% increase in weight from their baseline, and that patients with early weight gain [first 6 weeks] were more likely to gain even more weight," he said (*J. Clin. Psychiatry* 2005;66:1468-76).

I have type 2 diabetes. This is... my 24/7 glucose control

Covered on more than 90% of managed care plans!

Model is for illustrative purposes only.

Indications and usage

Levemir® is indicated for once- or twice-daily subcutaneous administration for the treatment of adult and pediatric patients with type 1 diabetes mellitus or adult patients with type 2 diabetes mellitus who require basal (long-acting) insulin for the control of hyperglycemia.

Important safety information

Levemir® is contraindicated in patients hypersensitive to insulin detemir or one of its excipients.

Hypoglycemia is the most common adverse effect of all insulin therapies, including Levemir®. As with other insulins, the timing of hypoglycemic events may differ among various insulin preparations. Glucose monitoring is recommended for all patients with diabetes. Levemir® is not to be used in insulin infusion pumps. Any change of insulin dose should be made cautiously and only under medical supervision. Concomitant oral antidiabetic treatment may require adjustment.

Inadequate dosing or discontinuation of treatment may lead to hyperglycemia and, in patients with type 1 diabetes, diabetic ketoacidosis. Levemir® should not be diluted or mixed with any

other insulin preparations. Insulin may cause sodium retention and edema, particularly if previously poor metabolic control is improved by intensified insulin therapy. Dose and timing of administration may need to be adjusted to reduce the risk of hypoglycemia in patients being switched to Levemir® from other intermediate or long-acting insulin preparations. The dose of Levemir® may need to be adjusted in patients with renal or hepatic impairment.

Other adverse events commonly associated with insulin therapy may include injection site reactions (on average, 3% to 4% of patients in clinical trials) such as lipodystrophy, redness, pain, itching, hives, swelling, and inflammation.

*Whether these observed differences represent true differences in the effects of Levemir®, NPH insulin, and insulin glargine is not known, since these trials were not blinded and the protocols (eg, diet and exercise instructions and monitoring) were not specifically directed at exploring hypotheses related to weight effects of the treatments compared. The clinical significance of the observed differences in weight has not been established.

For your patients with type 2 diabetes, start once-daily Levemir®

Levemir® helps patients with diabetes achieve their A1C goal.^{2,3}

- 24-hour action at a once-daily dose^{4,5}
- Provides consistent insulin absorption and action, day after day^{4,6,7}
- Less weight gain^{8*}

To access complimentary e-learning programs, visit novomedlink.com/Levemir

References: 1. Data on file. Novo Nordisk Inc, Princeton, NJ. 2. Meneghini LF, Rosenberg KH, Koenen C, Meriläinen MJ, Lüddeke H-J. Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICTIVE study. *Diabetes Obes Metab*. 2007;9(3):418-427. 3. Hermansen K, Davies M, Derezinski T, Ravn GM, Clauson P, Home P, for the Levemir Treat-to-Target Study Group. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. *Diabetes Care*. 2006;29(6):1269-1274. 4. Klein O, Lynge J, Endahl L, Damholt B, Nosek L, Heise T. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes. *Diabetes Obes Metab*. 2007;9(3):290-299. 5. Philis-Tsimikas A, Charpentier G, Clauson P, Ravn GM, Roberts VL, Thorsteinsson B. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. *Clin Ther*. 2006;28(10):1569-1581. 6. Danne T, Endahl L, Haahr H, et al. Lower within-subject variability in pharmacokinetic profiles of insulin detemir in comparison to insulin glargine in children and adolescents with type 1 diabetes. Presented at: 43rd Annual Meeting of the European Association for the Study of Diabetes; September 17-21, 2007; Amsterdam, Netherlands. Abstract 0189. 7. Heise T, Nosek L, Ronn BB, et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. *Diabetes*. 2004;53(6):1614-1620. 8. Data on file. NDA21-536. Novo Nordisk Inc, Princeton, NJ.



Please see brief summary of Prescribing Information on adjacent page.

FlexPen® and Levemir® are registered trademarks of Novo Nordisk A/S.
© 2008 Novo Nordisk Inc. 133236-R2 November 2008

